Clinical trials are undergoing a fundamental transformation. For decades, the success of a trial has been measured primarily through scientific rigour, regulatory compliance, recruitment numbers and the quality of clinical data generated. While these remain essential, the industry is increasingly recognising another factor as equally important: the patient experience.
Across Asia, where clinical research is expanding rapidly and patient populations are extraordinarily diverse, meaningful patient engagement can no longer be treated as an ancillary activity. It is emerging as a strategic imperative that can influence everything from protocol design and recruitment to retention, data quality and, ultimately, successful development and market access.
Historically, patients have often entered the clinical development process only after a protocol has been designed and a trial is ready to begin. The emerging model is different. Pharmaceutical companies and clinical research organisations are increasingly seeking patient perspectives before critical decisions are finalised. Early involvement can help development teams understand what matters most to patients, identify practical barriers to participation, and design trials around real-world needs rather than assumptions.
This shift is particularly important for Asia, with its diverse clinical research landscape spanning different healthcare systems, languages, cultures, socioeconomic conditions and health literacy levels. A trial design that works in one market may not translate effectively to another. Understanding patients early can improve recruitment, visit schedules, digital engagement, informed consent and communication.
Technology is transforming patient engagement through digital platforms, telemedicine, wearables and mobile apps. But its true value lies in building two-way relationships where patients actively contribute to research rather than simply provide data.
Early engagement can improve recruitment and retention by clarifying trial expectations, burdens and benefits. Patient input during protocol design can also identify unnecessary complexities, reduce participant burden and create a more patient-centred research experience.
For Asian pharma, this has implications well beyond individual trials. Patient engagement can become part of a broader strategy for building trust in clinical research. In markets where awareness of clinical trials varies considerably, transparent communication and genuine patient involvement can help address misconceptions and strengthen confidence among patients, caregivers and communities.
The strategic value of patient engagement extends to innovation. As precision medicine, decentralised trials, real-world evidence and patient-centric development advance, patient insights can help companies identify unmet needs and shape trial design, endpoints, digital tools and post-launch evidence strategies—driving more relevant and differentiated programmes.
Meaningful engagement goes beyond occasional advisory boards or surveys. It requires organisational commitment, strong governance, trained teams and clear processes for integrating patient insights into decision-making. Across Asia’s diverse populations, sponsors must also ensure engagement is inclusive, representative and culturally appropriate.
The question is no longer whether patients should have a voice in clinical research, but when that voice should be heard. Increasingly, the answer is clear: as early as possible.
For Asian pharma, early patient involvement offers an opportunity to move from conducting trials on patients to developing research programmes with them. This shift can make trials more practical, responsive and trusted, while aligning scientific innovation more closely with patient needs.
The future of clinical trials in Asia will be shaped not only by faster recruitment and advanced technologies, but also by how effectively the industry listens to the patients at the heart of clinical development.
In this issue, Charlotta Norgaard, Founder and CEO, Patient in Research writes about how patient engagement is transforming pharmaceutical research and development from a sponsor-driven process into a collaborative model centred on real patient needs.
Read the full article — it's free
Register with Pharma Focus Asia to unlock expert insights, research articles and in-depth industry analysis.
